SITE004-0156

SITE004 (DEU) › SITE004-0156

SITE004-0156

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-03-03

enrolled

AEs

5

Serious

2

Dropout signal

–

Adverse events

5

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-04 (study day 142); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 132); relationship: NOT RELATED

moderate assessed

Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 129); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 103); relationship: not assessed

mild assessed

Grade 1 Rash — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 26); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.